Want to see MDXH full AI Analyst Report?
MDXH Stock Chart & Stats
$0.41
-$0.01(-2.91%)
At close: 4:00 PM EDT
$0.41
-$0.01(-2.91%)
Day’s Range― - ―
52-Week Range$0.40 - $5.33
Previous CloseN/A
Volume391.95K
Average Volume (3M)626.41K
Market Cap
$20.94M
Enterprise Value$180.87
Total Cash (Recent Filing)$29.03M
Total Debt (Recent Filing)$95.11M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Aug 13, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding51,364,520
10 Day Avg. Volume359,371
30 Day Avg. Volume626,413
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-14.77
Price to Sales (P/S)1.66
P/FCF Ratio-15.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.25Price Target Upside692.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$111.20M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Scaling & GuidanceManagement set clear multi-quarter revenue targets focused on the core prostate cancer franchise, implying durable demand and scalable test volumes. Excluding Resolve, guidance signals the underlying business can grow high‑teens to mid‑20s percent, supporting reinvestment and longer‑term margin recovery if executed.
Healthy Gross Margins / Unit EconomicsSustained gross margins near 60% indicate favorable unit economics for molecular diagnostics tests. That margin profile provides structural leverage as revenue scales, allowing operating‑leverage opportunities to convert revenue growth into profitability over the medium term as fixed costs are absorbed.
Commercial Integration & Clinical InnovationSuccessful integration of ExoDx customers and cross‑training expands the sales team's addressable portfolio and efficiency, improving long‑term commercial reach. Coupled with AI platform work and the PROTECT trial, these initiatives can strengthen clinical differentiation and product stickiness across urologic oncology.
Bears Say
Balance-Sheet Leverage & Negative EquityRising debt and negative equity materially weaken financial flexibility, increasing refinancing and dilution risk. Elevated leverage constrains strategic optionality, raises interest and covenant sensitivity, and limits the firm's ability to absorb shocks or fund continued integration and R&D without costly capital.
Persistent Negative Cash FlowOperating and free cash flow remain negative despite improvement, meaning the company still relies on external funding to support operations and growth. Continued burn reduces runway and forces management to prioritize liquidity events, potentially delaying investments or prompting dilutive financings until cash flow turns sustainably positive.
Execution, Margin Compression & Reimbursement RiskAcquisition integration has lowered near‑term margins and widened pro‑forma operating losses, while the company faces a contested Novitas recoupment and has exited Resolve. These factors increase execution risk, may impose restructuring or appeal costs, and reduce revenue diversification, pressuring margins and cash needs into the medium term.
MDxHealth News
MDXH FAQ
What was Mdxhealth S.A.’s price range in the past 12 months?
Mdxhealth S.A. lowest stock price was $0.40 and its highest was $5.33 in the past 12 months.
What is Mdxhealth S.A.’s market cap?
Mdxhealth S.A.’s market cap is $20.94M.
When is Mdxhealth S.A.’s upcoming earnings report date?
Mdxhealth S.A.’s upcoming earnings report date is Aug 13, 2026 which is in 12 days.
How were Mdxhealth S.A.’s earnings last quarter?
Mdxhealth S.A. released its earnings results on May 13, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.145 by -$0.045.
Is Mdxhealth S.A. overvalued?
According to Wall Street analysts Mdxhealth S.A.’s price is currently Undervalued.
Does Mdxhealth S.A. pay dividends?
Mdxhealth S.A. does not currently pay dividends.
What is Mdxhealth S.A.’s EPS estimate?
Mdxhealth S.A.’s EPS estimate is -0.19.
How many shares outstanding does Mdxhealth S.A. have?
Mdxhealth S.A. has 51,364,520 shares outstanding.
What happened to Mdxhealth S.A.’s price movement after its last earnings report?
Mdxhealth S.A. reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.145. Following the earnings report the stock price went down -49.538%.
Which hedge fund is a major shareholder of Mdxhealth S.A.?
Currently, no hedge funds are holding shares in MDXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mdxhealth S.A.
MDxHealth SA (MDXH) is a molecular diagnostics company focused on urologic cancers, primarily prostate cancer. The company develops and commercializes genomic and epigenetic tests intended to help clinicians assess cancer risk and make more informed decisions about whether to pursue biopsy or treatment. Its core commercial products include prostate cancer testing such as Select mdx and Confirm mdx, marketed to support prostate cancer detection and risk stratification in clinical practice.
MDXH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but cautiously positive outlook: operationally the company is refocusing on its high-growth prostate cancer franchise with clear commercial integration wins (ExoDx transition, sales cross-training), AI initiatives, and a raised 2026 revenue target implying 20–26% growth. However, material near-term headwinds exist — most notably the strategic exit of the Resolve UTI business, a Novitas recoupment notice up to $10.4M, pro forma margin compression, and a wider operating loss driven by the ExoDx acquisition and integration — all of which create execution and liquidity considerations in the short term. Overall, management frames the Resolve exit as a proactive, value-accretive repositioning to prioritize scalable core growth while defending against payer recoupment risk.View all MDXH earnings summariesMDXH Stock 12 Month Forecast
Average Price Target
$3.25
▲(692.68% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.18% Mutual Funds
2.81% Other Institutional Investors
96.73% Public Companies and
Individual Investors